SPOTLIGHT: Organogenesis plans fast-paced expansion

Organogenesis CEO Geoff MacKay tells the Boston Globe about the reasons why the developer is staying and expanding at new facilities in Massachusetts. And he also discusses his "tight timeline" to expand production and gain new approvals over the next three to four years. Report

Suggested Articles

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.

RA Capital 's 15-month old inaugural venture fund that has already seen 25% of its portfolio companies IPO or be acquired.